Quantcast

Industry news that matters to you.  Learn more

Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck’s clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck’s lead investigational candidate for Alzheimer’s disease (AD). Financial terms were not disclosed.

Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare recently announced a clinical study collaboration, license and supply agreement for use of [18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck’s development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck’s lead investigational candidate for Alzheimer’s disease (AD).

NYAS Symposium: Biomarkers and Brain Imaging of Presymptomatic Alzheimer’s Disease

The New York Academy of Sciences (NYAS) will be holding an afternoon event in January 2012 that focuses on biomarkers and brain imaging of presymptomatic Alzheimer’s disease. Biomarkers and Brain Imaging of Presymptomatic Alzheimer’s Disease: Exploring the Silent Years will be held on Tuesday, January 24th, from 1pm – 5pm EST (10am – 2pm PST).